City of Hope Researcher Highlights Research in Amyloidosis [Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL)...].
In: Immunotherapy Weekly, 2023-12-19, S. 164-164
serialPeriodical
Zugriff:
A recent study conducted by researchers at City of Hope in Duarte, California, highlights the importance of addressing cardiac involvement in patients with AL amyloidosis. AL amyloidosis is a rare disorder characterized by the deposition of insoluble amyloid fibrils in vital organs, leading to organ dysfunction. The study aims to evaluate the safety, efficacy, and pharmacokinetics of a treatment regimen involving Daratumumab (DARA) plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a diverse patient population with newly diagnosed AL amyloidosis. The ongoing phase 2 AQUARIUS study will specifically focus on patients with cardiac involvement and racial or ethnic minorities to better understand the impact of the treatment on these populations. Efforts are being made to increase enrollment of minorities in clinical trials to ensure representative and diverse participation. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
City of Hope Researcher Highlights Research in Amyloidosis [Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL)...].
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2023-12-19, S. 164-164 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Sonstiges: |
|